For those old-school marijuana smokers who still sneak off to enjoy a guilt ridden cigarette, this new study published by J-Stage and sponsored by Japan’s Ministry of education, culture, sports, science and technology might provide some peace of mind. Japanese scientists have recently discovered that marijuana cannabinoids were strategic allies in fighting back a cancerous causing enzyme – CYP 1A1.
“CYP1A1 is expressed in various tissues including the liver and lung,14–16) although the constitutive expression level is very low. In general, hepatic and pulmonary CYP1A1 is induced by exposure to tobacco smoke.17,18) CYP1A1 is important in the bioactivation of procarcinogens, such as polycyclic aromatic hydrocarbons and heterocyclic amines.16,19) Furthermore, this enzyme plays a role in the metabolism of several drugs including granisetron20) and dacarbazine.21) Therefore, potent inhibition of CYP1A1 by CBD may not only lead to the suppression of metabolic activation of procarcinogens but also influence the pharmacokinetics of drugs metabolized mainly by CYP1A1. However, it is not clear which moiety of CBD contributes to potent direct CYP1A1 inhibition.”
The report summarized that their inhibition study clearly demonstrated ” that two free phenolic hydroxyl groups and the pentyl side chain in the pentylresorcinol moiety of CBD play important roles in direct CYP1A1 inhibition although the whole structure of CBD is essential for potent inhibition.